| DB ID | MyCo_3245 |
| Title | Association between circulating DNA, serum (1->3)-β-D-glucan, and pulmonary fungal burden in Pneumocystis pneumonia |
| Year | 2012 |
| PMID | 22523258 |
| Fungal Diseases involved | Pneumocystis pneumonia |
| Associated Medical Condition | None |
| Genus | Pneumocystis |
| Species | jirovecii |
| Organism | Pneumocystis jirovecii |
| Ethical Statement | This study was approved by the Henri Mondor Hospital Ethics Review Committee (IMCJ- H20-569). |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | France |
| Cohort | As part of a retrospective single-center, hospital-based cohort study involving all patients undergoing BAL to investigate the cause of pneumonia A total of 70 serum samples were collected from 63 patients, with 1 patient having 4 BALs and 4 patients 2 BALs (median intervals, 16 days; range, 15–318). |
| Cohort No. | 63 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay, qRT-PCR |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
